ReviewFrontiers in immunology2026
Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Dysregulated inflammation, characterized by the uncontrolled release of inflammatory mediators, is central to the pathogenesis of numerous inflammatory diseases, including acute sepsis and chronic rheumatoid arthritis (RA). Despite therapeutic advances in RA, limitations of current anti-inflammatory treatments-such as broad immunosuppression and partial efficacy-highlight an urgent need for novel interventions. This review critically examines the pathogenic roles of High Mobility Group Box 1 (HMGB1) and procathepsin-L (pCTS-L) in dysregulated inflammation, mediated by their interactions with Toll-like receptor 4 (TLR4) and the Receptor for Advanced Glycation End Products (RAGE). Crucially, we highlight the newly established HMGB1-pCTS-L axis, in which HMGB1 directly upregulates pCTS-L expression and release. This axis initiates a delayed yet sustained inflammatory loop, which may predominantly activate the more enduring non-canonical NF-κB pathway. Furthermore, we explore the intricate role of tetranectin (TN), an endogenous HMGB1-binding protein, which inhibits HMGB1 release but paradoxically facilitates HMGB1-induced pyroptosis. Leveraging this complexity, we introduce the TN-derived P2-1 peptide as a highly specific inhibitor of the HMGB1-pCTS-L axis. This peptide binds HMGB1 to prevent its RAGE engagement and subsequent macrophage pyroptosis, without broadly suppressing initial inflammatory cascades. It also specifically inhibits HMGB1-induced pCTS-L expression and release, ameliorating both sepsis and RA even with delayed treatment. Its "disease-triggered" mechanism, selectively targeting extracellular HMGB1 only at pathological sites, promises enhanced safety and precision. This review positions the HMGB1-pCTS-L axis as a critical and therapeutically tractable pathway, with HMGB1- and pCTS-L-inhibiting antibodies and mimetic peptides representing promising next-generation interventions for a spectrum of inflammatory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.